I think Neuren is in the middle of preparing for that (with the recent hire of Daryl DeKarske which by the way suggests to me that they are going to run 2 Phase 3 trials concurrently with the second trial starting perhaps 9-12 months after the start of PMS trial. Makes sense to me that if they want to increase value substantially in a shorter period of time they would run 2 trials together).
In the presentation it’s stated that Neuren plans to meet with the FDA before the end of this year to seek alignment on Phase 3 trial design for both Pitt Hopkins and Angelman syndrome, in addition to holding a pre-IND meeting for HIE.
NEU Price at posting:
$12.91 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)